LBRX — LB Pharmaceuticals Inc Common Stock
NASDAQ · Healthcare · Biotechnology
$46.55
-$0.55 (-1.17%)
LB Pharmaceuticals Inc Common Stock (LBRX) is a biotechnology company listed on NASDAQ. It is led by Heather D. Turner Esq., J.D., based in One Pennsylvania Plaza, New York, NY, United States, 10119, with about 35 employees. LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Net income was -$3.6M. LBRX currently screens at market cap $803.4M.
Use this LBRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LBRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LBRX SEC filings page. Lician reads the product cache first so this HTML stays unique to LB Pharmaceuticals Inc Common Stock even when a live quote feed is slow.
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
LBRX Key Statistics
Market Cap
$803.38M
Volume
106,700
Previous Close
$48.21
Day Range
$48.50 – $50.16
P/B Ratio
2.16
EPS
-$0.61
Revenue
$0.00
Net Income
-$3.56M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
35
LBRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2025 | FY2025 | FY2024 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$3.56M | -$4.87M | -$5.31M | -$14.18M | -$27.63M |
| EPS (Diluted) | -$0.61 | $0.00 | $0.00 | -$39.49 | $0.00 |
Total Assets
$320.75M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$269.74M
Operating Cash Flow
-$17.11M
Free Cash Flow
$0.00
LB Pharmaceuticals Inc Common Stock Company Information
- CEO & Director
- Heather D. Turner Esq., J.D.
- Headquarters
- One Pennsylvania Plaza, New York, NY, United States, 10119
- Website
- lbpharma.us
- Phone
- 212 605 0300
- IPO / Founded
- 2025-09-11
- Sector
- Healthcare
- Industry
- Biotechnology